|
|
Article: Nanobac Pharmaceuticals Announces New Research Study Evaluating Nanobacterial Endotoxin in Patients Undergoing Coronary Artery Angioplasty.
- Article from:
- Business Wire
- Article date:
- September 23, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
TAMPA, Fla.--(BUSINESS WIRE)--Sept. 23, 2003
Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP), announces approval of their Percutaneous Coronary Intervention (PCI) angioplasty research protocol by the Western Independent Review Board (WIRB(R), Seattle, WA). The Multi-Center PCI Study will be coordinated by the NanobacLabs Research Institute (Tampa, FL), the research subsidiary of Nanobac Pharmaceuticals, Inc., and will involve cardiologists at the University of Florida at Jacksonville, and Miami Heart Center.
The PCI study is being conducted to evaluate the presence of nanobacterial endotoxin, antigen and ...
Related newspaper, magazine, and journal articles:
|
|
Article: Issues Updates on Nanobac Pharmaceuticals, Inc.
M2 Presswire;
September 12, 2006 ;
700+ words
... ... limitless." About Nanobac Pharmaceuticals Nanobac Pharmaceuticals, Inc. is a life sciences ... calcification, particularly in coronary artery, prostate, and vascular ... from raw materials. Nanobac Pharmaceuticals, Inc. is headquartered ...
|
|